{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:46Z","timestamp":1791355786476,"version":"4.3.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Eculizumab, an antibody that inhibits the complement system, and the immunosuppressant Tacrolimus are both authorized for treating patients with generalized myasthenia gravis (GMG). This study seeks to evaluate and compare the clinical effectiveness of Eculizumab with or with not Tacrolimus in the treatment of generalized myasthenia gravis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was performed involving 95 patients with GMG treated with Eculizumab at three hospitals in China. Among them, 80 patients were included in the analysis: 57 received Eculizumab alone, while 23 were treated with a combination of Eculizumab and Tacrolimus. The main outcome assessed was the percentage of GMG patients who reached Minimal Symptom Expression (MSE). Secondary outcomes included changes in MG-Activities of Daily Living (MG-ADL) scale, Quantitative Myasthenia Gravis (QMG) score, CH50 concentration, and doses of pyridostigmine and prednisolone. Additionally, the safety profiles of both treatment groups were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the main outcome, a higher proportion of patients reached MSE status when treated with a combination of Eculizumab and Tacrolimus compared to Eculizumab alone (Eculizumab: 29 patients, 50.9% vs Eculizumab and Tacrolimus: 18 patients, 78.3%; p&amp;lt;0.05). Regarding secondary outcomes, both treatment groups showed significant improvements in clinical symptoms, as indicated by notable reductions in QMG and MG-ADL scores, along with a significant reduction in prednisolone dosage. Furthermore, analysis of secondary outcome parameters revealed no significant differences between the two groups (p&amp;gt;0.05). The decrease in complement CH50 concentration is accompanied by a decrease in QMG and MG-ADL scores, indicating that Eculizumab treats GMG through the mechanism of complement system. In terms of security, hyperuricemia was more commonly associated with the combination therapy of Eculizumab and Tacrolimus than with Eculizumab alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our research indicates that Eculizumab can effectively reduce disability in GMG patients by inhibiting complement system activation under real-world clinical conditions in China. We observed a correlative link between Eculizumab and Tacrolimus combination treatment and an increased probability of achieving MSE status, in comparison with Eculizumab monotherapy. However, combination therapy is associated with a higher risk of elevated serum uric acid among GMG patients, which necessitates regular close monitoring of renal function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1906981","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:52:10Z","timestamp":1791352330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical study of eculizumab with or with not tacrolimus in the treatment of generalized myasthenia gravis"],"prefix":"10.3389","volume":"17","author":[{"given":"Bin","family":"Yang","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, Tsinghua University School of Clinical Medicine","place":["Beijing, China"]},{"name":"Department of Neurology, Tsinghua University Yuquan Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tsinghua University Yuquan Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tsinghua University Yuquan Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuya","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tsinghua University Yuquan Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tsinghua University Yuquan Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s0011-5029(97)90033-x","article-title":"Myasthenia gravis","volume":"43","author":"Pourmand","year":"1997","journal-title":"Dis Mon"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"key":"B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/mus.28417","article-title":"Standardization of myasthenia gravis outcome measures in clinical practice: a report of the MGFA task force","volume":"72","author":"Ruzhansky","year":"2025","journal-title":"Muscle Nerve"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70563","article-title":"Minimal symptom expression in generalized myasthenia gravis: a valuable patient-centric treatment goal","volume":"33","author":"Meisel","year":"2026","journal-title":"Eur J Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.186.4158.55","article-title":"Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors","volume":"186","author":"Almon","year":"1974","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1016\/S0025-6196(25)09826-X","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(92)90024-9","article-title":"FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond","volume":"4","author":"Siekierka","year":"1992","journal-title":"Curr Opin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2019.60.7.633","article-title":"Long-term safety and efficacy of tacrolimus in myasthenia gravis","volume":"60","author":"Kim","year":"2019","journal-title":"Yonsei Med J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221122538","article-title":"Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort","volume":"13","author":"Bi","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39339.610000.be","article-title":"The declaration of helsinki","volume":"335","author":"Goodyear","year":"2007","journal-title":"Bmj"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis","volume":"31","author":"Yin","year":"2024","journal-title":"Eur J Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27422","article-title":"Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study","volume":"64","author":"Siddiqi","year":"2021","journal-title":"Muscle Nerve"},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S319500","article-title":"Clinical evaluation of the efficacy and safety of co-administration of Wuzhi capsule and tacrolimus in adult Chinese patients with myasthenia gravis","volume":"17","author":"Peng","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1667799","article-title":"Impacts of tacrolimus and glucocorticoids on peripheral blood T and B lymphocyte subsets in myasthenia gravis","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur J Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51746","article-title":"Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis","volume":"10","author":"Fan","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3791\/1923","article-title":"Measuring the 50% haemolytic complement (CH50) activity of serum","author":"Costabile","year":"2010","journal-title":"J Vis Exp"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114603","article-title":"Efficacy of multi-cycle efgartigimod in achieving minimal symptom expression in myasthenia gravis: a comparative multi-center study","volume":"154","author":"Chen","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010574","article-title":"Patient-acceptable symptom states in myasthenia gravis","volume":"95","author":"Mendoza","year":"2020","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1404191","article-title":"Targeting autoimmune mechanisms by precision medicine in myasthenia gravis","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696385","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"12","author":"Monteleone","year":"2021","journal-title":"Front Neurol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.neurol.2018.01.377","article-title":"Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets","volume":"175","author":"Bao","year":"2019","journal-title":"Rev Neurol (Paris)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.782980","article-title":"Evaluation of the quantitative myasthenia gravis score and grip strength in Chinese patients with myasthenia gravis: an observational study","volume":"12","author":"Li","year":"2021","journal-title":"Front Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241309431","article-title":"Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study","volume":"17","author":"Jin","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-026-00977-1","article-title":"Eculizumab in myasthenia gravis: a multicenter retrospective real-world study in China","volume":"15","author":"Li","year":"2026","journal-title":"Neurol Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"\u00c1lvarez-Velasco","year":"2021","journal-title":"Eur J Neurol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420904207","article-title":"Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12569-w","article-title":"United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use","volume":"271","author":"Habib","year":"2024","journal-title":"J Neurol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2019.02.004","article-title":"Effectiveness and safety of tacrolimus therapy for myasthenia gravis: a single arm meta-analysis","volume":"63","author":"Wang","year":"2019","journal-title":"J Clin Neurosci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8616-7","article-title":"Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"J Neurol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105630","article-title":"Temporal correlation between serum CH(50) level and symptom severity of myasthenia gravis during eculizumab therapy","volume":"189","author":"Yanagidaira","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ibneur.2026.03.011","article-title":"Perioperative use of eculizumab in patients with thymoma-associated myasthenia gravis: a preliminary case series of five patients","volume":"20","author":"Ou","year":"2026","journal-title":"IBRO Neurosci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70251","article-title":"Inhibition of classical and alternative complement pathway by ravulizumab and eculizumab","volume":"13","author":"Gerischer","year":"2026","journal-title":"Ann Clin Transl Neurol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","article-title":"Serum immunoglobulins and risk of infection: how low can you go","volume":"39","author":"Furst","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14153","article-title":"Serious infections in patients with myasthenia gravis: population-based cohort study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur J Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2022.02.027","article-title":"Lowering and raising serum urate levels: Off-label effects of commonly used medications","volume":"97","author":"Leung","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"B54","doi-asserted-by":"publisher","first-page":"116419","DOI":"10.1016\/j.jns.2019.08.004","article-title":"Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: a subgroup analysis of the REGAIN open-label extension study","volume":"407","author":"Murai","year":"2019","journal-title":"J Neurol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:52:11Z","timestamp":1791352331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2026.1906981"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1906981","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1906981"}}